A novel transcranial photobiomodulation device to address motor signs of Parkinson's disease: a parallel randomised feasibility study.

ABSTRACT:

Background

Parkinson's disease is a progressive neurological disease with limited treatment options. Animal models and a proof-of-concept case series have suggested that photobiomodulation may be an effective adjunct treatment for the symptoms of Parkinson's disease. The aim was to determine the safety and feasibility of transcranial photobiomodulation (tPBM) to reduce the motor signs of Parkinson's disease.

Methods

In this double-blind, randomised, sham-controlled feasibility trial, patients (aged 59-85 years) with idiopathic Parkinson's disease were treated with a tPBM helmet for 12 weeks (72 treatments with either active or sham therapy; stage 1). Treatment was delivered in the participants' homes, monitored by internet video conferencing (Zoom). Stage 1 was followed by 1

SUBMITTER: Herkes G 

PROVIDER: S-EPMC10716000 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature